Autoimmunerkrankungen mit Leberbeteiligung

Zu den primären autoimmunen Lebererkrankungen gehören: autoimmune Hepatitis, primär biliäre Cholangitis und primär sklerosierende Cholangitis. Sie sind zum Teil mit anderen Autoimmunerkrankungen assoziiert und müssen von systemischen immunologischen Erkrankungen mit Leberbeteiligung abgegrenzt werden. Dieser Beitrag widmet sich insbesondere der oft aufwendigen erforderlichen Diagnostik und der Therapie, der es die Patienten zuzuführen gilt.

Schlüsselwörter

autoimmune Hepatitis - primär biliäre Cholangitis - primär sklerosierende Cholangitis - Sarkoidose - IgG4-assoziierte Erkrankung

• Literatur

• 1 Vergani D, Alvarez F, Bianchi FB. et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683
• 2 Hennes EM, Zeniya M, Czaja AJ. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
• 3 Strassburg CP, Beckebaum S, Geier A. et al. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federführend). S2 k Leitlinie Autoimmune Lebererkrankungen. 2017 Im Internet: http://www.awmf.org/leitlinien/detail/ll/021-027.html Stand: 10.08.2017
• 4 Navarro VJ, Khan I, Björnsson E. et al. Liver injury from herbal and dietary supplements. Hepatology 2017; 65: 363-373
• 5 De Luca-Johnson J, Wangensteen KJ, Hanson J. et al. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci 2016; 61: 2710-2720
• 6 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004
• 7 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
• 8 Van Gerven NM, Verwer BJ, Witte BI. et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147
• 9 Beuers U, Gershwin ME, Gish RG. et al. Changing nomenclature for PBC: from ‘cirrhosisʼ to cholangitis’. Gastroenterology 2015; 149: 1627-1629
• 10 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145-172
• 11 Lammers WJ, Hirschfield GM, Corpechot C. et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149: 1804-1812
• 12 Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol 2014; 13: 316-326
• 13 Nevens F, Andreone P, Mazzella G. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375: 631-643
• 14 Schramm C, Eaton J, Ringe KI. et al. Recommendations on the use of MRI in PSC-A position statement from the International PSC study group. Hepatology 2017;
• 15 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
• 16 Aabakken L, Karlsen TH, Albert J. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017; 49: 588-608
• 17 Bergquist A, Ekbom A, Olsson R. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
• 18 Weiler-Normann C, Lohse AW. Variant syndromes of autoimmune liver diseases: classification, diagnosis and management. Dig Dis 2016; 34: 334-339
• 19 Kamisawa T, Zen Y, Pillai S. et al. IgG4-related disease. Lancet 2015; 385: 1460-1471
• 20 De Buy Wenniger LJ, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 2014; 60: 1453-1454
• 21 Syed U, Alkhawam H, Bakhit M. et al. Hepatic sarcoidosis: pathogenesis, clinical context, and treatment options. Scand J Gastroenterol 2016; 51: 1025-1030